Neurocrine Biosciences (NASDAQ:NBIX) Earns “Hold” Rating from Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a research note published on Tuesday morning, Benzinga reports.

Several other brokerages also recently weighed in on NBIX. Barclays lifted their target price on Neurocrine Biosciences from $145.00 to $150.00 and gave the company an overweight rating in a research note on Tuesday, January 23rd. JPMorgan Chase & Co. boosted their price objective on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an overweight rating in a research note on Wednesday, March 20th. StockNews.com raised Neurocrine Biosciences from a buy rating to a strong-buy rating in a research note on Thursday, February 8th. Wedbush reissued an outperform rating and issued a $147.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, April 17th. Finally, Cantor Fitzgerald reissued an overweight rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, April 10th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of Moderate Buy and a consensus target price of $142.38.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX opened at $137.76 on Tuesday. Neurocrine Biosciences has a 12-month low of $89.04 and a 12-month high of $148.37. The firm has a market capitalization of $13.71 billion, a P/E ratio of 56.93 and a beta of 0.25. The business has a 50 day simple moving average of $136.56 and a 200 day simple moving average of $127.69.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The business had revenue of $515.20 million during the quarter, compared to analyst estimates of $518.52 million. During the same quarter in the previous year, the firm posted $0.88 EPS. The business’s revenue for the quarter was up 25.0% compared to the same quarter last year. Research analysts anticipate that Neurocrine Biosciences will post 4.84 EPS for the current fiscal year.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Richard F. Pops sold 15,000 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total value of $1,987,050.00. Following the transaction, the director now owns 29,512 shares in the company, valued at $3,909,454.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Ingrid Delaet sold 5,000 shares of the company’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $145.06, for a total transaction of $725,300.00. Following the completion of the sale, the insider now owns 7,507 shares in the company, valued at approximately $1,088,965.42. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Richard F. Pops sold 15,000 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total value of $1,987,050.00. Following the sale, the director now owns 29,512 shares of the company’s stock, valued at approximately $3,909,454.64. The disclosure for this sale can be found here. Insiders have sold 186,994 shares of company stock worth $25,806,409 over the last 90 days. 4.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Neurocrine Biosciences

Several large investors have recently made changes to their positions in NBIX. Vanguard Group Inc. lifted its position in shares of Neurocrine Biosciences by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 9,710,328 shares of the company’s stock worth $1,279,433,000 after purchasing an additional 150,485 shares during the last quarter. DSM Capital Partners LLC lifted its position in shares of Neurocrine Biosciences by 15.4% during the 3rd quarter. DSM Capital Partners LLC now owns 1,224,017 shares of the company’s stock worth $137,702,000 after purchasing an additional 163,747 shares during the last quarter. Brown Advisory Inc. lifted its position in shares of Neurocrine Biosciences by 2.2% during the 4th quarter. Brown Advisory Inc. now owns 1,113,413 shares of the company’s stock worth $146,703,000 after purchasing an additional 23,831 shares during the last quarter. Braidwell LP lifted its position in shares of Neurocrine Biosciences by 3.7% during the 3rd quarter. Braidwell LP now owns 968,024 shares of the company’s stock worth $108,903,000 after purchasing an additional 34,662 shares during the last quarter. Finally, Los Angeles Capital Management LLC lifted its position in shares of Neurocrine Biosciences by 66.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock worth $121,007,000 after purchasing an additional 364,986 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.